CD133 在肝细胞癌中的作用。
The role of CD133 in hepatocellular carcinoma.
机构信息
Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
Department of Gastroenterology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
出版信息
Cancer Biol Ther. 2021 Apr 3;22(4):291-300. doi: 10.1080/15384047.2021.1916381. Epub 2021 Apr 25.
Abstract
Cancer stem cells (CSCs) represent a small subpopulation of cells found within tumors that exhibit properties of self-renewal, like normal stem cells. CSCs have been defined as a crucial factor involved in driving cancer relapse, chemoresistance and metastasis. Prominin-1 (CD133) is one of the most well-characterized markers of CSCs in various tumor types, including hepatocellular carcinoma (HCC). CD133+ cells have been demonstrated to be involved in metastasis, tumorigenesis, tumor recurrence, and resistance to treatment in HCC. CD133-related clinical prognosis prediction, and targeted therapy have highlighted the clinical significance of CD133 in HCC. However, there remains controversy over the role of CD133 in experimental and clinical research involving HCC. In this article, we summarize the fundamental cell biology of CD133 in HCC cells and discuss the important characteristics of CD133+ in HCC cells. Furthermore, the prognostic value of CD133, and therapeutic strategies for its targeting in HCC, is also reviewed.
摘要
癌症干细胞 (CSCs) 是肿瘤内发现的一小部分细胞，它们具有自我更新的特性，就像正常干细胞一样。CSCs 被定义为驱动癌症复发、化疗耐药和转移的关键因素。Prominin-1（CD133）是各种肿瘤类型中 CSCs 的最典型标志物之一，包括肝细胞癌 (HCC)。已经证明 CD133+细胞参与 HCC 的转移、肿瘤发生、肿瘤复发和对治疗的耐药性。CD133 相关的临床预后预测和靶向治疗突出了 CD133 在 HCC 中的临床意义。然而，在涉及 HCC 的实验和临床研究中，CD133 的作用仍存在争议。在本文中，我们总结了 CD133 在 HCC 细胞中的基本细胞生物学特性，并讨论了 CD133+在 HCC 细胞中的重要特征。此外，还回顾了 CD133 的预后价值及其在 HCC 中的靶向治疗策略。
相似文献
1
The role of CD133 in hepatocellular carcinoma.CD133 在肝细胞癌中的作用。
Cancer Biol Ther. 2021 Apr 3;22(4):291-300. doi: 10.1080/15384047.2021.1916381. Epub 2021 Apr 25.
2
CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma.CD133通过稳定肝细胞癌中的表皮生长因子受体-蛋白激酶B信号传导赋予癌症干细胞样特性。
Cancer Lett. 2017 Mar 28;389:1-10. doi: 10.1016/j.canlet.2016.12.023. Epub 2016 Dec 27.
3
G protein-coupled receptor 87 (GPR87) promotes the growth and metastasis of CD133⁺ cancer stem-like cells in hepatocellular carcinoma.G 蛋白偶联受体 87（GPR87）促进肝癌中 CD133⁺癌症干细胞样细胞的生长和转移。
PLoS One. 2013 Apr 10;8(4):e61056. doi: 10.1371/journal.pone.0061056. Print 2013.
4
CD133 cancer stem cells promoted by VEGF accelerate the recurrence of hepatocellular carcinoma.血管内皮生长因子促进的 CD133 肿瘤干细胞加速肝癌复发。
Sci Rep. 2017 Jan 30;7:41499. doi: 10.1038/srep41499.
5
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.CD133+肝癌癌干细胞通过优先表达Akt/PKB存活途径赋予化疗抗性。
Oncogene. 2008 Mar 13;27(12):1749-58. doi: 10.1038/sj.onc.1210811. Epub 2007 Sep 24.
6
A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM/CD133 nonStem Cells into EpCAM/CD133 Liver Cancer Stem Cells in HCC Cell Line HuH7.KLF4 在调控 EpCAM/CD133 非干细胞向 HCC 细胞系 HuH7 中的 EpCAM/CD133 肝癌干细胞去分化中的新功能。
Cells. 2020 May 12;9(5):1198. doi: 10.3390/cells9051198.
7
Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells.柳氮磺胺吡啶减弱CD133阳性肝癌细胞的逃避抗癌反应。
J Exp Clin Cancer Res. 2017 Mar 3;36(1):38. doi: 10.1186/s13046-017-0511-7.
8
Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.肝癌中 CD133+CD44+ 细胞群高度富集癌症干细胞/祖细胞。
Int J Cancer. 2010 May 1;126(9):2067-78. doi: 10.1002/ijc.24868.
9
ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α.ELK3通过靶向缺氧诱导因子-1α（HIF-1α）促进肝癌干细胞的迁移和侵袭。
Oncol Rep. 2017 Feb;37(2):813-822. doi: 10.3892/or.2016.5293. Epub 2016 Dec 7.
10
Inhibition of NOTCH signaling pathway chemosensitizes HCC CD133 cells to vincristine and 5-fluorouracil through upregulation of BBC3.抑制 NOTCH 信号通路通过上调 BBC3 使 HCC CD133 细胞对长春新碱和 5-氟尿嘧啶敏感。
Biochem Biophys Res Commun. 2020 May 14;525(4):941-947. doi: 10.1016/j.bbrc.2020.03.009. Epub 2020 Mar 12.
引用本文的文献
1
TREM1 is essential for maintaining stemness of liver cancer stem-like cells in hepatocellular carcinoma.触发受体表达于髓系细胞-1（TREM1）对于维持肝细胞癌中肝癌干细胞样细胞的干性至关重要。
Front Immunol. 2025 Jul 3;16:1618342. doi: 10.3389/fimmu.2025.1618342. eCollection 2025.
2
Inhibition of CD133 resulted in cell death, inhibition of angiogenesis, and limited migration in the melanoma cancer cell line.抑制CD133会导致黑色素瘤癌细胞系发生细胞死亡、抑制血管生成并限制迁移。
Mol Biol Rep. 2025 Jun 30;52(1):659. doi: 10.1007/s11033-025-10764-0.
3
Nanomaterials targeting cancer stem cells to overcome drug resistance and tumor recurrence.靶向癌症干细胞以克服耐药性和肿瘤复发的纳米材料。
Front Oncol. 2025 Jun 6;15:1499283. doi: 10.3389/fonc.2025.1499283. eCollection 2025.
4
Development of a circadian-related prognostic signature highlights RBM17 as a stemness regulator in liver cancer.一种与昼夜节律相关的预后特征的开发突出了RBM17作为肝癌干性调节因子的作用。
Cancer Cell Int. 2025 Jun 13;25(1):211. doi: 10.1186/s12935-025-03843-6.
5
Innovative applications of silicon dioxide nanoparticles for targeted liver cancer treatment.二氧化硅纳米颗粒在靶向肝癌治疗中的创新应用。
Front Bioeng Biotechnol. 2025 May 12;13:1595772. doi: 10.3389/fbioe.2025.1595772. eCollection 2025.
6
Application and prospect analysis of chimeric antigen receptor T-cell therapy in hepatocellular carcinoma treatment: a systematic review and meta-analysis.嵌合抗原受体T细胞疗法在肝细胞癌治疗中的应用及前景分析：一项系统评价与荟萃分析
Front Immunol. 2025 Apr 7;16:1566976. doi: 10.3389/fimmu.2025.1566976. eCollection 2025.
7
Folate receptor 1 is a stemness trait-associated diagnostic and prognostic marker for hepatocellular carcinoma.叶酸受体1是一种与肝细胞癌干性特征相关的诊断和预后标志物。
Biomark Res. 2025 Mar 4;13(1):37. doi: 10.1186/s40364-025-00752-8.
8
Multiomics in silico analysis identifies TM4SF4 as a cell surface target in hepatocellular carcinoma.多组学计算机模拟分析确定TM4SF4为肝细胞癌的细胞表面靶点。
PLoS One. 2025 Feb 25;20(2):e0307048. doi: 10.1371/journal.pone.0307048. eCollection 2025.
9
models of leukemia development: the role of very small leukemic stem-like cells in the cellular transformation cascade.白血病发展模型：极小的白血病干细胞样细胞在细胞转化级联反应中的作用
Front Cell Dev Biol. 2025 Jan 3;12:1463807. doi: 10.3389/fcell.2024.1463807. eCollection 2024.
10
The current socioeconomic and regulatory landscape of immune effector cell therapies.免疫效应细胞疗法当前的社会经济和监管环境。
Front Med (Lausanne). 2024 Dec 4;11:1462307. doi: 10.3389/fmed.2024.1462307. eCollection 2024.
本文引用的文献
1
An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells.基于适配体的药物递送剂（CD133-apt-Dox）可选择性和有效地杀死肝癌干细胞样细胞。
Cancer Lett. 2021 Mar 31;501:124-132. doi: 10.1016/j.canlet.2020.12.022. Epub 2020 Dec 19.
2
Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial.CD133靶向嵌合抗原受体T细胞治疗晚期肝细胞癌的疗效及生物标志物分析：一项单臂、开放标签的II期试验
Oncoimmunology. 2020 Nov 25;9(1):1846926. doi: 10.1080/2162402X.2020.1846926.
3
Irradiated mesenchymal stem cells support stemness maintenance of hepatocellular carcinoma stem cells through Wnt/β-catenin signaling pathway.经照射的间充质干细胞通过Wnt/β-连环蛋白信号通路支持肝癌干细胞干性的维持。
Cell Biosci. 2020 Aug 3;10:93. doi: 10.1186/s13578-020-00449-5. eCollection 2020.
4
Osthole resensitizes CD133 hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway.蛇床子素通过 PTEN/AKT 通路使 CD133 阳性肝癌细胞对顺铂重新敏感。
Aging (Albany NY). 2020 Jul 16;12(14):14406-14417. doi: 10.18632/aging.103484.
5
A new risk model comprising genes highly correlated with CD133 identifies different tumor-immune microenvironment subtypes impacting prognosis in hepatocellular carcinoma.一个包含与 CD133 高度相关的基因的新风险模型可识别不同的肿瘤免疫微环境亚型，影响肝细胞癌的预后。
Aging (Albany NY). 2020 Jun 20;12(12):12234-12250. doi: 10.18632/aging.103409.
6
A novel regulatory loop miR-101/ANXA2/EGR1 mediates malignant characteristics of liver cancer stem cells.一种新型调控环路miR-101/膜联蛋白A2/早期生长反应因子1介导肝癌干细胞的恶性特征。
Carcinogenesis. 2021 Feb 11;42(1):93-104. doi: 10.1093/carcin/bgaa055.
7
A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM/CD133 nonStem Cells into EpCAM/CD133 Liver Cancer Stem Cells in HCC Cell Line HuH7.KLF4 在调控 EpCAM/CD133 非干细胞向 HCC 细胞系 HuH7 中的 EpCAM/CD133 肝癌干细胞去分化中的新功能。
Cells. 2020 May 12;9(5):1198. doi: 10.3390/cells9051198.
8
Chromenopyrimidinone Controls Stemness and Malignancy by suppressing CD133 Expression in Hepatocellular Carcinoma.色烯并嘧啶酮通过抑制肝癌中CD133的表达来控制干性和恶性程度。
Cancers (Basel). 2020 May 8;12(5):1193. doi: 10.3390/cancers12051193.
9
Targeting the Epigenetic Non-Coding RNA MALAT1/Wnt Signaling Axis as a Therapeutic Approach to Suppress Stemness and Metastasis in Hepatocellular Carcinoma.靶向表观遗传非编码 RNA MALAT1/Wnt 信号轴抑制肝癌干细胞特性和转移的治疗策略。
Cells. 2020 Apr 20;9(4):1020. doi: 10.3390/cells9041020.
10
The DNMT1/miR-34a/FOXM1 Axis Contributes to Stemness of Liver Cancer Cells.DNMT1/miR-34a/FOXM1轴促成肝癌细胞的干性。
J Oncol. 2020 Apr 5;2020:8978930. doi: 10.1155/2020/8978930. eCollection 2020.
Zotero 插件